357 Results (Page 14 of 15)
Malaysia Markets Research Reports
Malaysia Conjunctivitis Therapeutics Market Analysis
The Malaysia Conjunctivitis Therapeutics Market was valued at $7 Mn in 2022 and is predicted to grow at a CAGR of 5.6% from 2023 to 2030, to $10 Mn by 2030. The key drivers of this industry include the surge in the burden of conjunctivitis, technological advancements in the industry, and supportive government initiatives. The industry is primarily dominated by players such as Bausch & Lomb, Roche, Novartis, AstraZeneca, and Johnson & Johnson among others.
Malaysia Head and Neck Cancer Therapeutics Market Analysis
The Malaysia Head and Neck Cancer Therapeutics Market was valued at $23.55 Mn in 2023 and is predicted to grow at a CAGR of 11.50% from 2023 to 2030, to $50.45 Mn by 2030. The key drivers of this industry include increasing cancer incidence, advanced treatment options, and government initiatives. The industry is primarily dominated by players such as Bristol Myers Squibb, Merck, Pfizer, and AstraZeneca among others.
Malaysia PET Scan Market Analysis
The Malaysia PET Scan Market was valued at $3.1 Mn in 2023 and is predicted to grow at a CAGR of 5.6% from 2023 to 2030, to $4.6 Mn by 2030. The key drivers of the market include increased healthcare expenditure, increased geriatric population, and rising prevalence of chronic diseases. The prominent players of the Malaysia PET Scan Market are GE Healthcare, Siemens Healthineers, Toshiba, Schiller, and Hitachi, among others.
Malaysia Mouth Ulcer Therapeutics Market Analysis
The Malaysia Mouth Ulcer Therapeutics Market was valued at $2.4 Mn in 2023 and is projected to grow at a CAGR of 4.1% from 2023 to 2023, to $3.2 Mn by 2030. The key drivers of this industry are rising awareness about oral hygiene, increasing demand for rapid healing products, growing geriatric population, rise in tobacco consumption, increasing incidence of oral diseases, chemical-based toothpaste and unhealthy lifestyles etc. The industry is primarily dominated by players such as Sanofi, CCM Pharmaceuticals, Duopharma Biotech Berhad, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer among others.
Malaysia Exosome Research Market Analysis
The Malaysia Exosome Research Market was valued at $0.2 Mn in 2023 and is projected to grow at a CAGR of 16.2% from 2023 to 2023, to $0.8 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Revery International Group Berhad, Thermo Fisher Scientific, Roche, System Biosciences LLC, Capricor Therapeutic among others.
Malaysia Bariatric Surgery Devices Market Analysis
The Malaysia Bariatric Surgery Devices Market was valued at $4.3 Mn in 2023 and is projected to grow at a CAGR of 5.4% from 2023 to 2023, to $6.2 Mn by 2030. Major factors driving the market for bariatric surgical devices include the rising incidence of adult obesity brought on by altered lifestyle patterns and excessive calorie consumption. The demand for bariatric operations is also anticipated to rise over the forecast period due to increased government backing and growing public awareness of the market's unhealthy food and beverage offerings and how they affect BMI, thus driving the market growth of the Bariatric Surgery Devices. The prominent players in the market are Medtronic, B. Braun, Asenus Surgical, Johnson & Johnson, Cousin Surgery among others.
Malaysia CT Scan Market Analysis
Malaysia CT Scan Market was valued at $7.41 Mn in 2023 and is predicted to grow at a CAGR of 8.07% from 2023 to 2030, to $12.76 Mn by 2030. The key drivers of this industry include the rising burden of chronic diseases, government initiatives, and growing technological advancements. The industry is primarily dominated by GE HealthCare, Siemens Healthineers, Canon Medical Systems, and NeuroLogica Corp. among others.
Malaysia Lipid Disorder Therapeutics Market Analysis
The Malaysia Lipid Disorder Therapeutics Market was valued at $194.9 Mn in 2023 and is predicted to grow at a CAGR of 11.63% from 2023 to 2030, to $421.1 Mn by 2030. Malaysia Lipid Disorder Therapeutics Market is growing due to Sedentary Lifestyles, Public Awareness and Early Intervention, Innovation, and New Treatment Options. The industry is primarily dominated by players such as Pharmaniaga Berhad, Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Malaysia Mental Health Apps Market Analysis
The Malaysia Mental Health Apps Market was valued at $9.97 Mn in 2023 and is predicted to grow at a CAGR of 15.4% from 2023 to 2030, to $27.17 Mn by 2030. The key drivers of this industry include increasing smartphone penetration, a shortage of professionals, and government support. The industry is primarily dominated by players such as HeadSpace, Calm, Happify, and PlusVibes among others.
Malaysia Bio-Implant Market Analysis
The Malaysia Bio-implant Market was valued at $104.5 Mn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030, to $158.2 Mn by 2030. The Malaysia Bio-implant Market is growing due to like Rising Prevalence of Chronic Diseases, Increasing Healthcare Expenditure, and Growing Medical Tourism Industry. The market is primarily dominated by players such as APEX Healthcare Berhad, Hartalega Holdings Berhad, Zimmer Biomet, Stryker Boston Scientific Corporation, Otto Bock Holding GmbH & Co. KG, and Medtronic plc.
Malaysia Constipation Therapeutics Market Analysis
Malaysia Constipation Therapeutics Market was valued at $29 Mn in 2022 and is estimated to reach $49 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The constipation therapeutics market is growing globally, propelled by factors like aging, sedentary lifestyles, and unhealthy dietary patterns, with the expanding elderly population, more prone to chronic conditions, contributing significantly to this expansion. Key players in this industry include Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, and Sanofi.
Malaysia Brain Cancer Therapeutics Market
Malaysia Brain Cancer Therapeutics Market valued at $4 Mn in 2022, projected to reach $8 Mn by 2030 with a 10.8% CAGR. The expected rise in instances of brain cancer, specifically glioblastoma multiforme, is projected to significantly enhance the demand for therapies aimed at treating brain cancer, thereby influencing the overall structure of the market. Top leading pharmaceutical companies presently operating in the market are Merck & Co, Amgen, Roche, Pfizer, Teva Pharmaceutical, Karyopharm Therapeutics, Novartis, AstraZeneca, Bristol Myers Squibb, and Eli Lilly.
Malaysia Herbal Supplements Market Report
Short Description The Malaysia Herbal Supplements Market was valued at $8.46 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030, to $13.06 Mn by 2030. The key drivers of this industry include disease burden, health consciousness, and government initiatives. The industry is primarily dominated by players such as Himalaya Wellness, Herbalife Nutrition, Dabur, and Patanjali Ayurved among others.
Malaysia Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Malaysia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $2.50 Mn in 2023 and is predicted to grow at a CAGR of 6.23% from 2023 to 2030, to $3.90 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Malaysia Brugada Syndrome Market Analysis
The Malaysia Brugada Syndrome Market was valued at $1.9 Mn in 2023 and is predicted to grow at a CAGR of 8.0% from 2023 to 2030, to $3.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and increased awareness. The prominent players of the Malaysia Brugada Syndrome Market are Novartis, Amgen, GSK, Merck, Sanofi, and Medtronic, among others.
Malaysia Dental Endodontics Market Analysis
Malaysia Dental Endodontics Market was valued at $2.80 Mn in 2023 and is predicted to grow at a CAGR of 4.5% from 2023 to 2030, to $3.80 Mn by 2030. The key drivers of this industry include rising demand for aesthetics, increasing prevalence of dental problems, and growing dental awareness. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
Malaysia Clinical Nutrition Market Analysis
The Malaysia Clinical Nutrition Market was valued at $49.3 Mn in 2023 and is projected to grow at a CAGR of 5.54% from 2023 to 2023, to $71.9 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Bioalpha, Yakult, Abbott Nutrition, Pfizer Inc, Bayer AG, Nestle, Baxter International Inc., Otsuka Holdings Co., Ltd, Mead Johnson & Company, LLC among others.
Malaysia Breast Pump Market Report
The Malaysia Breast Pump Market was valued at $4.7 Mn in 2023 and is predicted to grow at a CAGR of 8.8% from 2023 to 2030, to $8.5 Mn by 2030. The key drivers of the market include changing consumer preferences, increasing presence of females in the workforce, and growing consumer awareness. The prominent players of the Malaysia Breast Pump Market are Ameda, Pigeon, Horigen, Philips Avent, and Ardo Medical AG, among others.
Malaysia Cancer Induced Bone Disease Therapeutics Market
Malaysia Cancer Induced Bone Disease Therapeutics Market valued at $2 Mn in 2022, projected to reach $3 Mn by 2030 with a 6% CAGR. The key drivers of this industry include the increasing cancer incidence, government initiatives, and improved healthcare infrastructure. The industry is primarily dominated by players such as IHH Healthcare, Bayer, Merck, Pharmaniaga, Duopharma, Maypharm, Amgen, and Novartis among others.
Malaysia Congestive Heart Failure Therapeutics Market Analysis
The Malaysia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $17 Mn in 2022 to $26 Mn by 2030, with a CAGR of 6% during the forecast period of 2022-2030. The market in Malaysia is driven by the escalating incidence due to aging demographics and unhealthy lifestyle choices, supported by proactive government initiatives to enhance healthcare accessibility and affordability, along with the expanding coverage of CHF medications by insurance policies. Malaysia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, DuoPharma, Pharmaniaga, Hovid, Apex Bio, etc., among various others.
Malaysia Digital Biomarkers Market Analysis
Malaysia Digital Biomarkers Market was valued at $4.66 Mn in 2023 and is predicted to grow at a CAGR of 22.5% from 2023 to 2030, to $19.30 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, government initiatives, rising healthcare costs, and an aging population. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Malaysia Medication Access Programs Market Analysis
The Malaysia Medication Access Programs Market was valued at $8.8 Mn in 2023 and is predicted to grow at a CAGR of 14.8% from 2023 to 2030, to $23.2 Mn by 2030. The key drivers of this industry include disease burden, pharmaceutical industry growth, and government initiatives. The industry is primarily dominated by players such as Takeda Pharmaceuticals, Pfizer, Novartis, and Merck among others.
Malaysia Cardiac Resynchronization Therapy Market
Malaysia Cardiac Resynchronization Therapy Market valued at $8 Mn in 2022, projected to reach $12 Mn by 2030 with a 5.2% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, Nihon Kohden, Oscor, Siemens Healthineers, Sorin Group, MicroPort CRM, and Osram Health.
Malaysia Biosensors Market Analysis
The Malaysia Biosensors Market was valued at $46.5 Mn in 2023 and is predicted to grow at a CAGR of 8.2% from 2023 to 2030, to $80.7 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, emphasis on preventative care, and technological advancements. The prominent players of the Malaysia Biosensors Market are SD Biosensors, Meridian Bioscience, Biosensors International, Nix Biosensors, and Abbott Laboratories, among others.
Malaysia Physiotherapy Equipment Market Analysis
The Malaysia Physiotherapy Equipment Market was valued at $33.60 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030, to $55.39 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, expanding geriatric population, and advancements in technology. The key players in the industry are HMS Medical Systems, PhysioMalaysia, EMS Physio Ltd., and Synergy Rehab Pinnacle Rehab among others.
